Sales

–

–

–

–

Royalty and commission income*

–

–

–

–

Total revenues

–

–

–

–

Gross margin

–

–

–

–

Marketing and selling expenses*

–1.0

0.5

–2.4

0.1

Royalty and commission expenses*

–

–0.1

–

-

Administration expenses

–17.4

–14.4

–51.6

–42.8

Other operating expenses and income

–5.7

–4.8

–21.3

–18.9

Research and development

–

–

–

–

Operating result

–24.1

–15.4

–73.6

–58.3

Exceptional items

–

–

–1.2

–

Earnings before interest and tax (EBIT)

–24.1

–15.4

–74.8

–58.3

Net operating assets**

–

–

25.1

37.4

Segment liabilities**

–

–

–17.6

–15.7

Capital spending on property, plant and equipment

0.3

0.1

0.6

–

Investments in intangible assets

1.6

2.2

4.9

7.6

Depreciation

–1.2

–0.4

–2.3

–1.3

Impairment losses

–

–

–

–

Net cash flows from operating activities

–136.2

–64.8

–318.1

–329.9

Net cash flows from investing activities

48.8

–35.9

1,384.8

–1,076.2

Free cash flow

–127.9

–67.4

–324.6

–338.0

Underlying free cash flow

–124.6

–55.8

–305.9

–326.4

FCR in %

–

–

–

–

ROS in %

–

–

–

–

Merck Group

EUR million

Q3
2010

Q3
2009

Jan.-Sep.
2010

Jan.-Sep.
2009

Sales

2,347.0

1,862.3

6,472.6

5,445.6

Royalty and commission income*

90.8

87.7

272.1

272.6

Total revenues

2,437.8

1,950.0

6,744.7

5,718.2

Gross margin

1,818.2

1,428.1

5,121.2

4,221.8

Marketing and selling expenses*

–573.3

–446.2

–1,581.7

–1,366.8

Royalty and commission expenses*

–115.8

–105.2

–355.3

–303.8

Administration expenses

–128.0

–102.0

–347.5

–316.9

Other operating expenses and income

–91.0

–76.8

–335.4

–206.6

Research and development

–348.6

–332.8

–1,034.6

–986.3

Operating result

363.5

222.2

984.4

604.8

Exceptional items

–

–

–1.2

–68.8

Earnings before interest and tax (EBIT)

363.5

222.2

983.2

536.0

Net operating assets**

–

–

18,793.7

12,346.7

Segment liabilities**

–

–

–1,733.3

–1,401.0

Capital spending on property, plant and equipment

98.3

101.0

254.2

290.6

Investments in intangible assets

16.5

25.4

47.6

70.7

Depreciation

–292.9

–224.5

–740.5

–668.3

Impairment losses

–2.4

–8.7

–36.0

–8.9

Net cash flows from operating activities

558.0

535.5

1,302.9

1,010.5

Net cash flows from investing activities

–4,900.5

–169.8

–3,743.4

–1,436.4

Free cash flow

–4,382.9

399.0

–3,831.7

642.2

Underlying free cash flow

560.7

429.5

1,127.3

672.7

FCR in %

23.0

22.0

16.7

11.8

ROS in %

14.9

11.4

14.6

10.6